*kuch*
‘Proposal 6
New Member for the Board of Supervisory Directors.
This proposal is to appoint the candidate nominated by the Board of Supervisory Directors, Ms. Deborah A. Jorn MBA, as a new Member of the Board of Supervisory Directors and Chair of the Remuneration Committee to replace Mr. Jaap Blaak, who retired during 2018.
Ms. Jorn, (age: 60), is Board Director & Founder of Jorn Consulting LLC. She is currently Board Member of Viveve Medical Inc. since May 10, 2016. She has over 30 years of operational experience building specialty pharmaceutical businesses across numerous therapeutic areas in the U.S. and globally. Most recently, Ms. Jorn was Executive Vice President of Corporate and Commercial Development at Eyepoint Pharmaceuticals, a specialty pharmaceutical company focused on the developing and commercializing innovative ophthalmic products to treat serious eye diseases. Prior to joining Eyepoint, she was Executive Vice President and Group Company Chair at Bausch Health (formerly Valeant Pharmaceuticals) where she led the dermatology, gastroenterology and HAE businesses. Ms. Jorn was Chief Global Marketing Officer at Bausch & Lomb prior to its acquisition in 2013 by Bausch Health where she led the launch of several new products and the integration of Ista Pharmaceuticals following acquisition. Previously, she was Group Vice President of Women’s Healthcare and Fertility (2008-2010) and Allergy and Respiratory (2004-2008) at Schering Plough Corporation prior to its acquisition by Merck and Co., Inc. Ms. Jorn was also at Johnson & Johnson as the Worldwide Vice President of Internal Medicine and Early Commercial input. She began her career at Merck and for more than 20 years held roles of progressive responsibility in various
82042559 M 26423630 / 6
4
functional areas including R&D, Regulatory and Sales and Marketing. Ms. Jorn was also a Director of Orexigen Therapeutics, Inc. from May 2016 until July 2018.
PharmaVoice has recognized Ms. Jorn as “one of the top 100 most inspiring people in healthcare” in the “brand builders” category. Ms. Jorn holds an MBA degree with a combined major of Marketing and International Business from New York University Stern Graduate School of Business and a B.A. degree in Biochemistry from Rutgers University.
In the opinion of the Board of Supervisory Directors, Ms. Jorn represents a significant addition of excellent and relevant experience in building and maintaining strong brands in the US and globally, from the end of clinical development to maturity, and her abilities will be a strong addition to the Board of Supervisory Directors. The Board of Supervisory Directors has made a binding nomination to appoint Ms. Jorn as Supervisory Director of the Company for a period expiring at the Annual General Meeting to be held in the year 2023.
Ms. Jorn holds no shares in the Company.’
*kuch*